| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AC4 A RETROSPECTIVE COHORT STUDY OF MEDICATION ADHERENCE TO TREATMENT OF OSTEOPOROSIS IN A SWEDISH POPULATION
|
Landfeldt, E
|
|
2009
|
12 |
Supplement 1 |
p. A221-
1 p.
|
artikel
|
| 2 |
A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective
|
St Charles, Meaghan
|
|
2009
|
12 |
Supplement 1 |
p. 674-686
13 p.
|
artikel
|
| 3 |
A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson's Disease
|
Visser, Martine
|
|
2009
|
12 |
Supplement 1 |
p. 392-396
5 p.
|
artikel
|
| 4 |
An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
|
Chen, Wen
|
|
2009
|
12 |
Supplement 1 |
p. S82-S84
3 p.
|
artikel
|
| 5 |
A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire
|
Pickard, A. Simon
|
|
2009
|
12 |
Supplement 1 |
p. 977-988
12 p.
|
artikel
|
| 6 |
Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises
|
Krol, Marieke
|
|
2009
|
12 |
Supplement 1 |
p. 172-180
9 p.
|
artikel
|
| 7 |
Budget Impact and Cost-Effectiveness of Including a Pentavalent Rotavirus Vaccine in the New Zealand Childhood Immunization Schedule
|
Milne, Richard J.
|
|
2009
|
12 |
Supplement 1 |
p. 888-898
11 p.
|
artikel
|
| 8 |
Calibration of Disease Simulation Model Using an Engineering Approach
|
Kong, Chung Yin
|
|
2009
|
12 |
Supplement 1 |
p. 521-529
9 p.
|
artikel
|
| 9 |
Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods
|
Bojke, Laura
|
|
2009
|
12 |
Supplement 1 |
p. 739-749
11 p.
|
artikel
|
| 10 |
CN3 COST-EFFECTIVENESS OF SORAFENIB IN UNRESECTABLE AND/OR METASTATIC RENAL CELL CARCINOMA IN TURKEY
|
Tatar, M
|
|
2009
|
12 |
Supplement 1 |
p. A222-
1 p.
|
artikel
|
| 11 |
CN5 COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY
|
Schuler, US
|
|
2009
|
12 |
Supplement 1 |
p. A224-A225
nvt p.
|
artikel
|
| 12 |
CO2 ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS
|
Hoyle, M
|
|
2009
|
12 |
Supplement 1 |
p. A233-
1 p.
|
artikel
|
| 13 |
CO4 COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIAL
|
Dinan, M
|
|
2009
|
12 |
Supplement 1 |
p. A7-
1 p.
|
artikel
|
| 14 |
Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia
|
Friedman, Howard
|
|
2009
|
12 |
Supplement 1 |
p. 1135-1143
9 p.
|
artikel
|
| 15 |
Cost-Effectiveness of Drug-Eluting Stents in a US Medicare Setting: A Cost-Utility Analysis with 3-Year Clinical Follow-Up Data
|
Bischof, Matthias
|
|
2009
|
12 |
Supplement 1 |
p. 649-656
8 p.
|
artikel
|
| 16 |
Cost-Effectiveness of New-Generation Oral Cholera Vaccines: A Multisite Analysis
|
Jeuland, Marc
|
|
2009
|
12 |
Supplement 1 |
p. 899-908
10 p.
|
artikel
|
| 17 |
Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy
|
Ramsey, Scott D.
|
|
2009
|
12 |
Supplement 1 |
p. 217-225
9 p.
|
artikel
|
| 18 |
Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease
|
Hay, Joel W.
|
|
2009
|
12 |
Supplement 1 |
p. 262-266
5 p.
|
artikel
|
| 19 |
Costs of Medication Nonadherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature
|
Salas, Maribel
|
|
2009
|
12 |
Supplement 1 |
p. 915-922
8 p.
|
artikel
|
| 20 |
Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries
|
Virués-Ortega, Javier
|
|
2009
|
12 |
Supplement 1 |
p. 385-391
7 p.
|
artikel
|
| 21 |
CS10 ANÁLISIS DE COSTO EFECTIVIDAD Y COSTO UTILIDAD DEL INTERFERÓN BETA-1B (INFB1B) FRENTE A INTERFERÓN BETA-1A (INFB1A) PARA EL TRATAMIENTO DE ESCLEROSIS MÚLTIPLE REMITENTE RECIDIVANTE EN COLOMBIA
|
Romero, M
|
|
2009
|
12 |
Supplement 1 |
p. A487-
1 p.
|
artikel
|
| 22 |
CS14 ASSESSMENT OF THE ECONOMICAL IMPACT OF NON-PERSISTENCE WITH ANTIDEPRESSANT TREATMENTS USING THE ADMINISTRATIVE CLAIMS DATABASE OF QUEBEC (CANADA)
|
Beland, SG
|
|
2009
|
12 |
Supplement 1 |
p. A490-
1 p.
|
artikel
|
| 23 |
CS13 CLINICAL EFFECTIVENESS AND COST UTILITY OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS IN MEXICO
|
Rely, K
|
|
2009
|
12 |
Supplement 1 |
p. A490-
1 p.
|
artikel
|
| 24 |
CS17 COSTOS DE LA ESCLEROSIS MÚLTIPLE EN COLOMBIA
|
Romero, M
|
|
2009
|
12 |
Supplement 1 |
p. A491-
1 p.
|
artikel
|
| 25 |
DB1 USING POPULATION-BASED ESTIMATES FOR DISEASE MODELING: POTENTIAL BIAS COMPARED TO USING DISEASE-SPECIFIC DEATH AND COMPLICATION RISK ESTIMATES
|
Goeree, R
|
|
2009
|
12 |
Supplement 1 |
p. A234-
1 p.
|
artikel
|
| 26 |
Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire
|
Grimison, Peter S.
|
|
2009
|
12 |
Supplement 1 |
p. 800-807
8 p.
|
artikel
|
| 27 |
DU1 PHYSICAL FUNCTION AND THE CONCOMITANT USE OF ANTICHOLINERGIC ANTIHISTAMINES AND CHOLINESTERASE INHIBITORS AMONG MEDICAID RECIPIENTS WITH DEMENTIA
|
Modi, A
|
|
2009
|
12 |
Supplement 1 |
p. A3-
1 p.
|
artikel
|
| 28 |
EE8 BRIDGING HEALTH TECHNOLOGY ASSESSMENT WITH MULTICRITERIA DECISION ANALYSIS (MCDA) AND AN ETHICAL FRAMEWORK FOR COMPLEX DECISIONS: CASE STUDY OF GROWTH HORMONE FOR TURNER SYNDROME
|
Goetghebeur, MM
|
|
2009
|
12 |
Supplement 1 |
p. A230-
1 p.
|
artikel
|
| 29 |
Effects of Mode and Order of Administration on Generic Health-Related Quality of Life Scores
|
Hays, Ron D.
|
|
2009
|
12 |
Supplement 1 |
p. 1035-1039
5 p.
|
artikel
|
| 30 |
Enhancing Value of Information Analyses
|
Janssen, Mart P.
|
|
2009
|
12 |
Supplement 1 |
p. 935-941
7 p.
|
artikel
|
| 31 |
Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
|
Cella, David
|
|
2009
|
12 |
Supplement 1 |
p. 124-129
6 p.
|
artikel
|
| 32 |
Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression
|
Herbild, Louise
|
|
2009
|
12 |
Supplement 1 |
p. 560-567
8 p.
|
artikel
|
| 33 |
Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire
|
Askew, Robert L.
|
|
2009
|
12 |
Supplement 1 |
p. 1144-1150
7 p.
|
artikel
|
| 34 |
Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States
|
Kim, Sunny
|
|
2009
|
12 |
Supplement 1 |
p. 267-272
6 p.
|
artikel
|
| 35 |
Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist
|
Meads, David M.
|
|
2009
|
12 |
Supplement 1 |
p. 397-400
4 p.
|
artikel
|
| 36 |
Health-Related Quality of Life (HRQL) and Continuous Antipsychotic Treatment: 3-year Results from the Schizophrenia Health Outcomes (SOHO) Study
|
Alonso, Jordi
|
|
2009
|
12 |
Supplement 1 |
p. 536-543
8 p.
|
artikel
|
| 37 |
Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore
|
Sun, Yan
|
|
2009
|
12 |
Supplement 1 |
p. S101-S105
5 p.
|
artikel
|
| 38 |
Impact of Patient Selection Criteria and Treatment History on Comparisons of Alternative Therapies: A Case Study of Atypical Antipsychotics
|
Marshall, Thomas S.
|
|
2009
|
12 |
Supplement 1 |
p. 473-480
8 p.
|
artikel
|
| 39 |
Large Impact of Antidiabetic Drug Treatment and Hospitalizations on Economic Burden of Diabetes Mellitus in The Netherlands during 2000 to 2004
|
van der Linden, Michiel W.
|
|
2009
|
12 |
Supplement 1 |
p. 909-914
6 p.
|
artikel
|
| 40 |
MD1 NONADHERENCE WITH ORAL HYPOGLYCEMICS AMONG MEDICARE PART D ENROLLEES WITH DIABETES
|
Yang, Y
|
|
2009
|
12 |
Supplement 1 |
p. A12-
1 p.
|
artikel
|
| 41 |
MD6 PREDICTORS OF UTILIZATION OF ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS AMONG MEDICARE PART D ENROLLEES WITH DIABETES
|
Yang, Y
|
|
2009
|
12 |
Supplement 1 |
p. A15-
1 p.
|
artikel
|
| 42 |
MD4 THE EFFECT OF MEDICARE PART D ON INAPPROPRIATE PSYCHOTROPIC MEDICATION USE IN THE ELDERLY
|
Chen, H
|
|
2009
|
12 |
Supplement 1 |
p. A12-
1 p.
|
artikel
|
| 43 |
Modeling Length of Stay in Hospital and Other Right Skewed Data: Comparison of Phase-Type, Gamma and Log-Normal Distributions
|
Faddy, Malcolm
|
|
2009
|
12 |
Supplement 1 |
p. 309-314
6 p.
|
artikel
|
| 44 |
MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R
|
Bischof, M
|
|
2009
|
12 |
Supplement 1 |
p. A226-A227
nvt p.
|
artikel
|
| 45 |
Multinational Trials—Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report
|
Wild, Diane
|
|
2009
|
12 |
Supplement 1 |
p. 430-440
11 p.
|
artikel
|
| 46 |
Obesity and Incremental Hospital Charges among Patients with and without Diabetes in the United States
|
Kim, Sunny
|
|
2009
|
12 |
Supplement 1 |
p. 723-729
7 p.
|
artikel
|
| 47 |
Patient Experiences of Continuity of Cancer Care: Development of a New Medical Care Questionnaire (MCQ) for Oncology Outpatients
|
Harley, Clare
|
|
2009
|
12 |
Supplement 1 |
p. 1180-1186
7 p.
|
artikel
|
| 48 |
PCASE2 REMUNERAÇÃO BASEADA EM PERFORMANCE: O QUE EXISTE DE DIFERENTE DA CONSULTA BONIFICADA UTILIZADA EM ALGUMAS UNIMEDS
|
Abicalaffe, CL
|
|
2009
|
12 |
Supplement 1 |
p. A528-A529
nvt p.
|
artikel
|
| 49 |
PCN90 A METHODOLOGICAL INVESTIGATION TO DEFINE A CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE
|
Quinten, C
|
|
2009
|
12 |
Supplement 1 |
p. A53-
1 p.
|
artikel
|
| 50 |
PCN154 ANTICANCER DRUG EXPENDITURE IN CATALONIA 2003–2007
|
Paladio Duran, N
|
|
2009
|
12 |
Supplement 1 |
p. A286-
1 p.
|
artikel
|
| 51 |
PCN109 BREAST CANCER PREVALENCE AND HEALTH CARE UTILIZATION AND COST TRENDS AMONG FEE-FOR-SERVICE FEMALE RECIPIENTS IN A STATE MEDICAID PROGRAM
|
Khanna, R
|
|
2009
|
12 |
Supplement 1 |
p. A56-A57
nvt p.
|
artikel
|
| 52 |
PCN64 CHARACTERIZING RESOURCE USE AND TREATMENT COSTS FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE UK (UK)
|
Szabo, SM
|
|
2009
|
12 |
Supplement 1 |
p. A268-
1 p.
|
artikel
|
| 53 |
PCN49 COLORECTAL CANCER SCREENING FOR AVERAGE RISK INDIVIDUALS: AN ECONOMIC EVALUATION
|
Au, F
|
|
2009
|
12 |
Supplement 1 |
p. A45-
1 p.
|
artikel
|
| 54 |
PCN8 COMORBIDITIES IN PATIENTS WITH METASTATIC COLORECTAL CANCER
|
Fu, AZ
|
|
2009
|
12 |
Supplement 1 |
p. A257-
1 p.
|
artikel
|
| 55 |
PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE: A NUMBER NEEDED TO TREAT ANALYSIS
|
Rugo, H
|
|
2009
|
12 |
Supplement 1 |
p. A260-
1 p.
|
artikel
|
| 56 |
PCN81 COST EFFECTIVENESS ANALYSIS OF BORTEZOMIB IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS IN CANADA
|
Yoong, K
|
|
2009
|
12 |
Supplement 1 |
p. A272-
1 p.
|
artikel
|
| 57 |
PCN24 COST-EFFECTIVENESS ANALYSIS OF LAPATINIB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE AND OF TRASTUZUMAB ASSOCIATED TO CAPECITABINE VERSUS CAPECITABINE ALONE IN THE TREATMENT OF METASTATIC BREAST CANCER UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
Supplement 1 |
p. A497-
1 p.
|
artikel
|
| 58 |
PCN78 COST-EFFECTIVENESS ASSESSMENT OF ZOLEDRONIC ACID (ZOL) RELATIVE TO PLACEBO (PBO) IN THE TREATMENT OF LUNG CANCER PATIENTS WITH SKELETAL METASTASES IN FIVE EUROPEAN COUNTRIES
|
Botteman, MF
|
|
2009
|
12 |
Supplement 1 |
p. A271-
1 p.
|
artikel
|
| 59 |
PCN95 COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA
|
Kim, JH
|
|
2009
|
12 |
Supplement 1 |
p. A275-
1 p.
|
artikel
|
| 60 |
PCN35 COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE IN COLOMBIA IN 2007
|
de La Hoz, F
|
|
2009
|
12 |
Supplement 1 |
p. A42-
1 p.
|
artikel
|
| 61 |
PCN112 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE
|
Bastide, P
|
|
2009
|
12 |
Supplement 1 |
p. A278-
1 p.
|
artikel
|
| 62 |
PCN40 COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN
|
Calderero, V
|
|
2009
|
12 |
Supplement 1 |
p. A263-
1 p.
|
artikel
|
| 63 |
PCN32 ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/ INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL
|
Greenberg, D
|
|
2009
|
12 |
Supplement 1 |
p. A42-
1 p.
|
artikel
|
| 64 |
PCN18 ECONOMIC IMPACT OF SEVERE INFUSION REACTIONS IN PATIENTS WITH COLORECTAL CANCER TREATED WITH CETUXIMAB
|
Foley, KA
|
|
2009
|
12 |
Supplement 1 |
p. A39-
1 p.
|
artikel
|
| 65 |
PCN21 ESTUDIO DE COSTO EFECTIVIDAD DEL USO DE TRASTUZUMAB COMO TRATAMIENTO ADYUVANTE DEL CÁNCER DE MAMA TEMPRANO HER2 POSITIVO EN EL INSTITUTO NACIONAL DE CANCEROLOGÍA DE COLOMBIA, DESDE EL PUNTO DE VISTA DEL PAGADOR
|
Díaz, JA
|
|
2009
|
12 |
Supplement 1 |
p. A496-
1 p.
|
artikel
|
| 66 |
PCN37 EXPECTED ECONOMIC BURDEN OF TREATING ADVANCED SOFT TISSUE SARCOMAS WITH TRABECTEDIN IN RUSSIA
|
Avxentyeva, M
|
|
2009
|
12 |
Supplement 1 |
p. A263-
1 p.
|
artikel
|
| 67 |
PCN129 FACTORS AFFECTING ADMINISTRATION REGIMES AND COSTS ASSOCIATED WITH EIGHT FIRST-LINE CHEMOTHERAPEUTIC DRUGS IN SEVEN COMBINATIONS, IN THE TREATMENT OF MNSCLC
|
Rosery, H
|
|
2009
|
12 |
Supplement 1 |
p. A281-A282
nvt p.
|
artikel
|
| 68 |
PCN50 HOSPITALISATIONS FOR HEAD AND NECK CANCERS IN FRANCE
|
Lacau St Guily, J
|
|
2009
|
12 |
Supplement 1 |
p. A265-A266
nvt p.
|
artikel
|
| 69 |
PCN126 LOSS OF WORK ACTIVITY AND PRODUCTIVITY IN CAREGIVERS ATTENDING TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA TREATED WITH TEMSIROLIMUS OR INTERFERON-ALFA: EVALUATIONS FROM A PHASE 3 RANDOMIZED TRAIL
|
Yang, S
|
|
2009
|
12 |
Supplement 1 |
p. A281-
1 p.
|
artikel
|
| 70 |
PCN7 METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
|
Teich, V
|
|
2009
|
12 |
Supplement 1 |
p. A493-A494
nvt p.
|
artikel
|
| 71 |
PCN93 ONCOLOGIC PATIENT SATISFACTION IN ONCOLOGIC SERVICES IN A TERTIARY REFERRAL CENTER AT THE SOCIAL SECURITY MEXICAN INSTITUTE
|
Contreras-Hernandez, I
|
|
2009
|
12 |
Supplement 1 |
p. A54-
1 p.
|
artikel
|
| 72 |
PCN144 PATTERNS OF EMPLOYMENT AFTER CANCER: RESULTS OF A LONGITUDINAL STUDY
|
de Moor, J
|
|
2009
|
12 |
Supplement 1 |
p. A284-
1 p.
|
artikel
|
| 73 |
PCN5 RENAL CELL CARCINOMA PATIENTS ARE TWICE AS LIKELY TO DEVELOP THROMBOEMBOLIC EVENTS COMPARED TO CANCER-FREE CONTROLS
|
van Herk-Sukel, MPP
|
|
2009
|
12 |
Supplement 1 |
p. A256-A257
nvt p.
|
artikel
|
| 74 |
PCN169 REVIEW OF THE DECISIONS OF HEALTH TECHNOLOGY ASSESSMENT AGENCIES FOR CAPECITABINE FOR THE TREATMENT OF BREAST CANCER
|
Saggia, MG
|
|
2009
|
12 |
Supplement 1 |
p. A289-
1 p.
|
artikel
|
| 75 |
PCN76 REVISITING CHERNOBYL: THE LONG-RUN IMPACT OF THE NUCLEAR ACCIDENT ON LABOR MARKET OUTCOMES
|
Zelenska, T
|
|
2009
|
12 |
Supplement 1 |
p. A50-
1 p.
|
artikel
|
| 76 |
PCN3 THE FEASIBILITY AND COST OF EARLY DETECTION OF PROSTATE CANCER IN GASTROENTEROLOGY UNITS
|
Shafran-Tikva, S
|
|
2009
|
12 |
Supplement 1 |
p. A36-
1 p.
|
artikel
|
| 77 |
PCN172 TREATMENT PATTERNS AMONG PATIENTS WITH ADVANCED BREAST CANCER PREVIOUSLY TREATED WITH AN ANTHRACYCLINE AND A TAXANE: A RETROSPECTIVE LONGITUDINAL STUDY
|
Colman, S
|
|
2009
|
12 |
Supplement 1 |
p. A290-
1 p.
|
artikel
|
| 78 |
PCN38 TREATMENT PATTERNS OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE TO ANTHRACYCLINE AND TAXANE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
|
Serrano, SV
|
|
2009
|
12 |
Supplement 1 |
p. A500-
1 p.
|
artikel
|
| 79 |
PCV14 A COMPARISON OF BLOOD PRESSURE OUTCOMES ASSOCIATED WITH THE USE OF ANGIOTENSIN-RECEPTOR BLOCKERS (ARBS) IN PATIENTS SEEN PREDOMINANTLY IN PRIMARY CARE PRACTICES
|
Biskupiak, J
|
|
2009
|
12 |
Supplement 1 |
p. A314-
1 p.
|
artikel
|
| 80 |
PCV166 ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE IMAGING IN SUSPECTED CORONARY ARTERY DISEASE: A NET COST ANALYSIS & REIMBURSEMENT IMPLICATIONS
|
Pilz, G
|
|
2009
|
12 |
Supplement 1 |
p. A344-
1 p.
|
artikel
|
| 81 |
PCV41 ADHERENCE TO GUIDELINES FOR SENSITIVITY ANALYSIS: COSTEFFECTIVENESS ANALYSES OF DUAL ORAL ANTIPLATELET THERAPY
|
Mauskopf, J
|
|
2009
|
12 |
Supplement 1 |
p. A148-
1 p.
|
artikel
|
| 82 |
PCV28 BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POPULATION ANALYSIS OF NET CLINICAL BENEFIT
|
Schmitt, C
|
|
2009
|
12 |
Supplement 1 |
p. A317-
1 p.
|
artikel
|
| 83 |
PCV93 CARDIOVASCULAR RISK (ACCORDING TO FRAGMINHAN) FOLLOW-UP OF A COHORT INSCRIBED IN THE DE TODO CORAZON (DTC) DISEASE MANAGEMENT PROGRAMME OF MUTUAL SER HMO IN COLOMBIA, 2004–2007
|
Paz, J
|
|
2009
|
12 |
Supplement 1 |
p. A158-
1 p.
|
artikel
|
| 84 |
PCV14 CLINICAL AND ECONOMIC OUTCOMES IN PATIENTS SWITCHED TO SIMVASTATIN IN A COMMUNITY-BASED PRIMARY CARE SETTING
|
Willey, VJ
|
|
2009
|
12 |
Supplement 1 |
p. A143-
1 p.
|
artikel
|
| 85 |
PCV42 CONFORMATION OF BLEEDING QUANTITY MEASURED AFTER HEART OPERATIONS ACCORDING TO METEOROLOGICAL AND ASTRONOMICAL FACTORS
|
Paljunite, A
|
|
2009
|
12 |
Supplement 1 |
p. A319-
1 p.
|
artikel
|
| 86 |
PCV17 COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN 10 MG VS. ATORVASTATIN 20 MG FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
|
Anaya, P
|
|
2009
|
12 |
Supplement 1 |
p. A503-
1 p.
|
artikel
|
| 87 |
PCV59 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN
|
Espallardo, O
|
|
2009
|
12 |
Supplement 1 |
p. A323-
1 p.
|
artikel
|
| 88 |
PCV103 COST-EFFECTIVENESS OF EXTENDED VERSUS NON-EXTENDED PROPHYLAXIS WITH ENOXAPARIN IN HIGH-RISK SURGICAL PATIENTS IN AUSTRALIA
|
Tilden, D
|
|
2009
|
12 |
Supplement 1 |
p. A332-
1 p.
|
artikel
|
| 89 |
PCV14 COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA
|
Castro, D
|
|
2009
|
12 |
Supplement 1 |
p. A502-
1 p.
|
artikel
|
| 90 |
PCV86 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE
|
Fagnani, F
|
|
2009
|
12 |
Supplement 1 |
p. A328-
1 p.
|
artikel
|
| 91 |
PCV55 COST-EFFECTIVENESS OF VALSARTAN IN JAPAN: RESULTS FROM THE JIKEI HEART STUDY
|
Shimizu, M
|
|
2009
|
12 |
Supplement 1 |
p. A151-
1 p.
|
artikel
|
| 92 |
PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND—A DISCRETE EVENT SIMULATION MODELLING
|
Soini, EJ
|
|
2009
|
12 |
Supplement 1 |
p. A335-
1 p.
|
artikel
|
| 93 |
PCV45 DETERMINING A MODEL-DERIVED RELATIVE STROKE RISK THRESHOLD TO JUSTIFY CAROTID STENTING IN SURGICAL HIGH-RISK PATIENTS
|
Smolen, HJ
|
|
2009
|
12 |
Supplement 1 |
p. A320-
1 p.
|
artikel
|
| 94 |
PCV163 GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS: AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION
|
Zhao, Z
|
|
2009
|
12 |
Supplement 1 |
p. A344-
1 p.
|
artikel
|
| 95 |
PCV148 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA
|
Müller-Nordhorn, J
|
|
2009
|
12 |
Supplement 1 |
p. A341-
1 p.
|
artikel
|
| 96 |
PCV73 INCREASED PATIENT THROUGHPUT AND REDUCTION IN LABORATORY STAFF AND LABOR INTENSITY WITH THE USE OF REGADENOSON
|
Smalarz, AM
|
|
2009
|
12 |
Supplement 1 |
p. A154-A155
nvt p.
|
artikel
|
| 97 |
PCV131 NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK: THE IMPACT OF GASTROINTESTINAL SYMPTOMS
|
Sörstadius, E
|
|
2009
|
12 |
Supplement 1 |
p. A337-A338
nvt p.
|
artikel
|
| 98 |
PCV90 PHARMACEUTICAL SPENDING ON CHRONIC DISEASES IN CONSUMER DIRECTED HEALTH PLANS
|
Kadiyala, S
|
|
2009
|
12 |
Supplement 1 |
p. A157-
1 p.
|
artikel
|
| 99 |
PCV134 PREDICTORS OF NON-PERSISTENCE ON STATIN TREATMENTS IN ITALY: A RETROSPECTIVE
|
Cammarota, S
|
|
2009
|
12 |
Supplement 1 |
p. A338-
1 p.
|
artikel
|
| 100 |
PCV107 SPECIFICITY OF ADMINISTRATIVE DATA FOR IDENTIFYING HEART FAILURE PATIENTS FOR HOSPITAL QUALITY PERFORMANCE INITIATIVES
|
Bautista, A
|
|
2009
|
12 |
Supplement 1 |
p. A161-
1 p.
|
artikel
|
| 101 |
PCV100 THE RELATIONSHIP BETWEEN HIGH DENSITY LIPOPROTEIN CHOLESTEROL (HDL-C), NICOTINIC ACID AND ALL-CAUSE MORTALITY
|
Simons, WR
|
|
2009
|
12 |
Supplement 1 |
p. A331-
1 p.
|
artikel
|
| 102 |
PCV58 TRIAL-BASED ECONOMIC EVALUATION ALONGSIDE THE TCYB (TAKE CONTROL OF YOUR BLOOD PRESSURE) TRIAL
|
Reed, SD
|
|
2009
|
12 |
Supplement 1 |
p. A152-
1 p.
|
artikel
|
| 103 |
PCV11 UNDERSTANDING THE IMPACT OF STATIN TITRATION; A MODELLING APPROACH
|
Gray, AM
|
|
2009
|
12 |
Supplement 1 |
p. A313-
1 p.
|
artikel
|
| 104 |
PCV31 US BUDGET IMPACT OF INCREASING ASPIRIN USAGE FOR PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE
|
Benedict, A
|
|
2009
|
12 |
Supplement 1 |
p. A146-
1 p.
|
artikel
|
| 105 |
PDB75 APPLICATION OF HTA TO ANTIDIABETIC DRUG FORMULARY DECISIONS
|
Andreykiv, M
|
|
2009
|
12 |
Supplement 1 |
p. A415-A416
nvt p.
|
artikel
|
| 106 |
PDB65 ASSOCIATIONS BETWEEN PATIENT-REPORTED DIABETES KNOWLEDGE AND HEALTH OUTCOMES, SELF-CARE, AND PREFERENCES FOR POTENTIALLY-BENEFICIAL NEW TREATMENT OPTIONS
|
Bruhn, D
|
|
2009
|
12 |
Supplement 1 |
p. A109-
1 p.
|
artikel
|
| 107 |
PDB27 COST-EFFECTIVENESS OF EXENATIDE VERSUS INSULIN GLARGINE FOR THE TREATMENT OF TYPE-2 DIABETES IN TURKEY: A LONG-TERM HEALTH ECONOMIC ANALYSIS
|
Bruhn, D
|
|
2009
|
12 |
Supplement 1 |
p. A406-
1 p.
|
artikel
|
| 108 |
PDB1 COSTS OF INSULIN GLARGINE AND INSULIN DETEMIR IN INTENSIVE INSULIN THERAPY FOR TYPE 1 DIABETES MELLITUS IN ARGENTINA: A PROBABILISTIC MODEL
|
Pichon-Riviere, A
|
|
2009
|
12 |
Supplement 1 |
p. A505-
1 p.
|
artikel
|
| 109 |
PDB41 COST-UTILITY OF INSULIN GLARGINE IN COMBINATION THERAPY WITH ORAL AGENTS COMPARED WITH PREMIX INSULIN WITH OR WITHOUT OF ORAL AGENTS IN TYPE 2 DIABETES. THE POLISH PERSPECTIVE
|
Dziewiatka, M
|
|
2009
|
12 |
Supplement 1 |
p. A409-
1 p.
|
artikel
|
| 110 |
PDB22 ECONOMIC EVALUATION OF LONG-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE-1 AND TYPE-2 DIABETES MELLITUS IN CANADA
|
Belanger, D
|
|
2009
|
12 |
Supplement 1 |
p. A101-
1 p.
|
artikel
|
| 111 |
PDB23 ECONOMIC EVALUATION OF METFORMIN, METFORMIN + SIBUTRAMIN OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS
|
Salinas Escudero, G
|
|
2009
|
12 |
Supplement 1 |
p. A101-
1 p.
|
artikel
|
| 112 |
PDB21 ECONOMIC EVALUATION OF RAPID-ACTING INSULIN ANALOGUES FOR THE TREATMENT OF PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS IN CANADA
|
Belanger, D
|
|
2009
|
12 |
Supplement 1 |
p. A100-
1 p.
|
artikel
|
| 113 |
PDB6 EVALUACIÓN DE LOS COSTOS ASOCIADOS A LA ELECCIÓN DE LA INSULINA: EL DILEMA DE LOS PAGADORES
|
Bustamante, H
|
|
2009
|
12 |
Supplement 1 |
p. A506-
1 p.
|
artikel
|
| 114 |
PDB44 EXAMINING THE RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND MEDICATION ADHERENCE IN DIABETIC PATIENTS
|
Pinto, SL
|
|
2009
|
12 |
Supplement 1 |
p. A409-A410
nvt p.
|
artikel
|
| 115 |
PDB12 GLYCATED HAEMOGLOBIN AS A SURROGATE MARKER FOR THE APPEARANCE AND PROGRESSION OF RETINOPATHY IN TYPE-1 DIABETES MELLITUS: SYSTEMATIC REVIEW AND META-ANALYSIS
|
Wieczorek, A
|
|
2009
|
12 |
Supplement 1 |
p. A403-
1 p.
|
artikel
|
| 116 |
PDB9 IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE
|
Huse, D
|
|
2009
|
12 |
Supplement 1 |
p. A402-A403
nvt p.
|
artikel
|
| 117 |
PDB26 RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE
|
White-Means, S
|
|
2009
|
12 |
Supplement 1 |
p. A101-
1 p.
|
artikel
|
| 118 |
PDB9 THE EFFECTS OF SUSTAINED-RELEASE GLIPIZIDE VERSUS GLICLAZIDE FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS
|
Wang, L
|
|
2009
|
12 |
Supplement 1 |
p. A98-
1 p.
|
artikel
|
| 119 |
PDB41 THE HANDLING OF GLUCOSE MONITORING AND INSULIN TREATMENT (HAGLUMIT) QUESTIONNAIRE CAPTURES HANDLING DIFFERENCES BETWEEN DIFFERENT SITUATIONS AND SYSTEMS FOR MONITORING BLOOD GLUCOSE IN DIABETES
|
Mast, O
|
|
2009
|
12 |
Supplement 1 |
p. A104-
1 p.
|
artikel
|
| 120 |
PDB58 THE “WHO, HOW AND THEN WHAT…” OF INSULIN INITIATION IN UK PRIMARY CARE
|
Smith, HT
|
|
2009
|
12 |
Supplement 1 |
p. A412-
1 p.
|
artikel
|
| 121 |
PDB55 UTILIZATION OF ANTIDIABETIC MEDICATIONS OF PATIENTS WITH TYPE 2 DIABETES COVERED BY VARIOUS TYPES OF HEALTH INSURANCE IN A US NATIONAL REPRESENTATIVE POPULATION IN YEAR 2005–2006
|
Deng, L
|
|
2009
|
12 |
Supplement 1 |
p. A107-
1 p.
|
artikel
|
| 122 |
PG120 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE—BLIND CLINICAL TRIAL
|
Iyer, S
|
|
2009
|
12 |
Supplement 1 |
p. A349-
1 p.
|
artikel
|
| 123 |
PGI2 CHRONIC HEPATITIS C VIRUS (HCV) TREATMENT COSTS IN THE TERTIARY REFERENCE HOSPITAL DAS CLÍNICAS—UNIVERSITY OF SÃO PAULO SCHOOL OF MEDICINE (HC-FMUSP)
|
Nabeshima, MA
|
|
2009
|
12 |
Supplement 1 |
p. A508-
1 p.
|
artikel
|
| 124 |
PGI11 ECONOMIC EVALUATION OF INFLIXIMAB AND ADALIMUMAB FOR CROHN'S DISEASE
|
Hughes, DA
|
|
2009
|
12 |
Supplement 1 |
p. A59-
1 p.
|
artikel
|
| 125 |
PGI14 RESPONSIVENESS TO CHANGE AND CONSTRUCT VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR GASTROESOPHAGEAL REFLUX DISEASE (WPAI : GERD) IN SWEDISH PATIENTS
|
Wahlqvist, P
|
|
2009
|
12 |
Supplement 1 |
p. A60-
1 p.
|
artikel
|
| 126 |
PG14 SYSTEMATIC REVIEW: THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHN'S DISEASE
|
Assasi, N
|
|
2009
|
12 |
Supplement 1 |
p. A346-
1 p.
|
artikel
|
| 127 |
PHC7 DEVELOPMENT AND VALIDATION OF SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HALITOSIS: THE HALITOSIS QUALITY OF LIFE QUESTIONNAIRE (HQLQ)
|
Taieb, C
|
|
2009
|
12 |
Supplement 1 |
p. A63-
1 p.
|
artikel
|
| 128 |
PHP70 ASSESSING THE EFFECT OF COST-SHARING ON EMERGENCY DEPARTMENT USE BY ECONOMICALLY DISADVANTAGED PERSONS
|
Strassels, SA
|
|
2009
|
12 |
Supplement 1 |
p. A91-
1 p.
|
artikel
|
| 129 |
PHP30 A SYSTEMATIC LITERATURE REVIEW OF ELECTRONIC MONITORING DEVICES FOR MEASURING MEDICATION ADHERENCE
|
Shi, L
|
|
2009
|
12 |
Supplement 1 |
p. A84-
1 p.
|
artikel
|
| 130 |
PHP13 CALCULATION OF DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN SIMPLIFIED PROCEDURE IN HUNGARY
|
Nagy, Z
|
|
2009
|
12 |
Supplement 1 |
p. A239-A240
nvt p.
|
artikel
|
| 131 |
PHP74 ELECTROMAGNETIC INTERFERENCES BETWEEN WIRELESS COMMUNICATION TECHNOLOGY AND CRITICAL CARE MEDICAL EQUIPMENT: A HEALTH TECHNOLOGY ASSESSMENT
|
Bouza, C
|
|
2009
|
12 |
Supplement 1 |
p. A250-A251
nvt p.
|
artikel
|
| 132 |
PHP15 EVALUATION OF SEVERITY SCORING INDICES IN ACUTE ORGANOPHOSPHORUS POISONED PATIENTS IN A TERTIARY CARE HOSPITAL
|
Thunga, G
|
|
2009
|
12 |
Supplement 1 |
p. A511-
1 p.
|
artikel
|
| 133 |
PHP57 GLOBAL PRICING AND REIMBURSEMENT (P & R) TRENDS: FURTHER DEVELOPMENTS IN SUPPLY AND DEMAND SIDE CONTROLS FOR MEDICINES
|
Mallinson, M
|
|
2009
|
12 |
Supplement 1 |
p. A247-
1 p.
|
artikel
|
| 134 |
PHP73 HEALTH TECHNOLOGY ASSESSMENT IN DEVELOPING COUNTRIES: WHAT IS THE STATE OF PLAY?
|
Shankland, B
|
|
2009
|
12 |
Supplement 1 |
p. A92-
1 p.
|
artikel
|
| 135 |
PHP91 IMPLANTABLE LOOP RECORDERS IN UNEXPLAINED TRANSIENT LOSS OF CONSCIOUSNESS (T-LOC) DIAGNOSTICS: A COST-SAVING OPPORTUNITY FOR THE UK NATIONAL HEALTH SERVICE (NHS)
|
Petkar, S
|
|
2009
|
12 |
Supplement 1 |
p. A254-
1 p.
|
artikel
|
| 136 |
PHP16 PARALLEL TRADE OF PHARMACEUTICALS IN POLAND
|
Baran-Lewandowska, I
|
|
2009
|
12 |
Supplement 1 |
p. A240-
1 p.
|
artikel
|
| 137 |
PHP60 PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES
|
Shepelev, J
|
|
2009
|
12 |
Supplement 1 |
p. A248-
1 p.
|
artikel
|
| 138 |
PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK
|
Mansour, E
|
|
2009
|
12 |
Supplement 1 |
p. A242-A243
nvt p.
|
artikel
|
| 139 |
PHP26 THE IMPACT OF MEDICARE PART D ON MEDICARE-MEDICAID DUAL-ELIGIBLE BENEFICIARIES' PRESCRIPTION UTILIZATION AND EXPENDITURES
|
Basu, A
|
|
2009
|
12 |
Supplement 1 |
p. A83-
1 p.
|
artikel
|
| 140 |
PHP11 THE IMPACT OF NON-REFERRAL OUTPATIENT CO-PAYMENT ON MEDICAL CARE UTILISATION AND EXPENDITURE IN TAIWAN
|
Chen, LC
|
|
2009
|
12 |
Supplement 1 |
p. A80-A81
nvt p.
|
artikel
|
| 141 |
PHP87 THE IMPACT OF THE SUBMISSION SEQUENCE – WHICH APPRAISING BODY TO SUBMIT TO FIRST?
|
Karia, R
|
|
2009
|
12 |
Supplement 1 |
p. A94-A95
nvt p.
|
artikel
|
| 142 |
PHP45 THE RAPID ADOPTION OF HEALTH TECHNOLOGY ASSESSMENT IN MIDDLE INCOME COUNTRIES—WHAT INFLULENCE DOES IT HAVE ON PHARMACEUTICAL REIMBURSEMENT. RESULTS FROM A SURVEY OF HEALTH CARE DECISION-MAKERS IN 11 COUNTRIES
|
White, J
|
|
2009
|
12 |
Supplement 1 |
p. A245-
1 p.
|
artikel
|
| 143 |
PHP55 TRENDS IN DESIGN CHARACTERISTICS OF BRIEF SUMMARY ON PRINT ADS OF PRESCRIPTION DRUGS: A FIVE YEAR STUDY
|
Dwibedi, N
|
|
2009
|
12 |
Supplement 1 |
p. A88-
1 p.
|
artikel
|
| 144 |
PHP44 WILLINGNESS TO PAY FOR PHARMACIST'S DISPENSING SERVICE: A CROSS SECTIONAL PILOT STUDY IN THE STATE OF PENANG, MALAYSIA
|
Shafie, AA
|
|
2009
|
12 |
Supplement 1 |
p. A86-
1 p.
|
artikel
|
| 145 |
PIH15 AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG / ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA
|
Jung, S
|
|
2009
|
12 |
Supplement 1 |
p. A293-
1 p.
|
artikel
|
| 146 |
PIH12 ANÁLISE DA APRESENTAÇÃO GRÁFICA DA BULA DE MEDICAMENTO NA PERSPECTIVA DAS ESTRATÉGIAS LEITURA DE PACIENTES EM CONTEXTO DE USO
|
Fujita, P
|
|
2009
|
12 |
Supplement 1 |
p. A514-A515
nvt p.
|
artikel
|
| 147 |
PIH39 ASSOCIATION BETWEEN SEXUAL DRIVE CHANGE AND PREMENSTRUAL SYMPTOMS
|
Yang, M
|
|
2009
|
12 |
Supplement 1 |
p. A169-
1 p.
|
artikel
|
| 148 |
PIH14 COST-EFFECTIVENESS OF NEONATAL SCREENING FOR CONGENITAL ERRORS OF METABOLISM USING TANDEM MASS SPECTROMETRY
|
Ramos Goñi, J
|
|
2009
|
12 |
Supplement 1 |
p. A164-
1 p.
|
artikel
|
| 149 |
PIH7 COST OF PNEUMONIA HOSPITALIZATION IN ELDERLY PEOPLE FROM TWO LARGE BRAZILIAN HOSPITALS
|
Toniolo, J
|
|
2009
|
12 |
Supplement 1 |
p. A514-
1 p.
|
artikel
|
| 150 |
PIH33 DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA
|
Petric, M
|
|
2009
|
12 |
Supplement 1 |
p. A296-
1 p.
|
artikel
|
| 151 |
PIH11 ECONOMIC EVALUATION ALONGSIDE THE CAFFEINE FOR APNEA OF PREMATURITY (CAP) TRIAL: SHORT TERM OUTCOMES
|
Dukhovny, D
|
|
2009
|
12 |
Supplement 1 |
p. A164-
1 p.
|
artikel
|
| 152 |
PIH14 THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND
|
Jensen, JAG
|
|
2009
|
12 |
Supplement 1 |
p. A292-
1 p.
|
artikel
|
| 153 |
PIH28 THE IMPACT OF MEDICARE SUPPLEMENT INSURANCE ON ACCESS, UTILIZATION, AND COST OF HEALTH CARE AND ON COMPLIANCE WITH RECOMMENDED PHARMACEUTICAL TREATMENT
|
Marshall, JK
|
|
2009
|
12 |
Supplement 1 |
p. A167-
1 p.
|
artikel
|
| 154 |
PIH29 VALIDATION AND CROSS-NATIONAL EQUIVALENCE OF THE EYELASH SATISFACTION QUESTIONNAIRE
|
Burgess, SM
|
|
2009
|
12 |
Supplement 1 |
p. A295-
1 p.
|
artikel
|
| 155 |
PIN13 ANÁLISIS COSTO EFECTIVIDAD DE PRUEBAS RÁPIDAS PARA EL DIAGNÓSTICO DEL VIH COMO HERRAMIENTA DE PREVENCIÓN Y CONTROL DE LA EPIDEMIA
|
Caso, A
|
|
2009
|
12 |
Supplement 1 |
p. A517-
1 p.
|
artikel
|
| 156 |
PIN8 BUDGET-IMPACT ANALYSIS OF ADDING THE NEW 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINATION (PHID-CV) TO ROUTINE INFANT VACCINATION IN CANADA
|
Ismaila, AS
|
|
2009
|
12 |
Supplement 1 |
p. A418-
1 p.
|
artikel
|
| 157 |
PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA
|
Dimitrova, MJ
|
|
2009
|
12 |
Supplement 1 |
p. A419-
1 p.
|
artikel
|
| 158 |
PIN26 CLINICAL AND ECONOMIC IMPACTS OF BACTEREMIA CAUSED BY EXTENDED-SPECTRUM BETA-LACTAMASES PRODUCING ESCHERICHIACOLI IN HONG KONG
|
Mok, SS
|
|
2009
|
12 |
Supplement 1 |
p. A422-
1 p.
|
artikel
|
| 159 |
PIN17 COST EFFECTIVE FOR HPV VACCINE
|
Cheng, IN
|
|
2009
|
12 |
Supplement 1 |
p. A112-A113
nvt p.
|
artikel
|
| 160 |
PIN40 COST-EFFECTIVENESS OF DORIPENEM IN THE TREATMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN MEXICO
|
Soto-Molina, H
|
|
2009
|
12 |
Supplement 1 |
p. A424-A425
nvt p.
|
artikel
|
| 161 |
PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
|
Jensen, DM
|
|
2009
|
12 |
Supplement 1 |
p. A427-
1 p.
|
artikel
|
| 162 |
PIN34 DOES COMBINING ANTIRETROVIRAL AGENTS IN TO A SINGLE DOSAGE FORM (CO-FORMULATIONS) ENHANCE QUALITY OF LIFE OF HIV/AIDS PATIENTS-A COST UTILITY STUDY
|
Ganguli, A
|
|
2009
|
12 |
Supplement 1 |
p. A116-
1 p.
|
artikel
|
| 163 |
PIN3 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN THERAPY FOR THE TREATMENT OF CANDIDEMIA AND PNEUMONIA INFECTIONS
|
Schaffer, K
|
|
2009
|
12 |
Supplement 1 |
p. A110-
1 p.
|
artikel
|
| 164 |
PIN50 MICAFUNGIN VS CASPOFUNGIN FOR THE TREATMENT OF SYSTEMIC CANDIDA INFECTIONS: A COST-EFFECTIVENESS ANALYSIS FOR GERMANY
|
Felder, S
|
|
2009
|
12 |
Supplement 1 |
p. A426-A427
nvt p.
|
artikel
|
| 165 |
PIN81 MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS
|
Endel, G
|
|
2009
|
12 |
Supplement 1 |
p. A432-A433
nvt p.
|
artikel
|
| 166 |
PIN49 NEW ANTIFUNGAL MEDICATION IMPACT ON MARKET SHARE AND UTILIZATION OF TRADITIONAL AGENTS IN A SINGLE HEALTH CARE SYSTEM
|
Cavanaugh, TM
|
|
2009
|
12 |
Supplement 1 |
p. A119-
1 p.
|
artikel
|
| 167 |
PIN67 QUALITY OF LIFE AND HEALTH CARE UTILIZATION BURDEN OF HCV-INFECTED PATIENTS IN EUROPE
|
Zhang, HF
|
|
2009
|
12 |
Supplement 1 |
p. A430-
1 p.
|
artikel
|
| 168 |
PIN14 THE COST-EFFECTIVENESS OF TRUVADA, KIVEXA AND COMBIVIR IN THE TREATMENT OF ANTIRETROVIRAL NAÏVE HIV-1 INFECTED PATIENTS IN MEXICO
|
Rely, K
|
|
2009
|
12 |
Supplement 1 |
p. A112-
1 p.
|
artikel
|
| 169 |
PIN31 THE ECONOMICS AND EPIDEMIOLOGY OF MENINGOCOCCAL INFECTION: A SYSTEMATIC LITERATURE REVIEW
|
Whitesell, E
|
|
2009
|
12 |
Supplement 1 |
p. A115-
1 p.
|
artikel
|
| 170 |
PMC13 A QALY ALTERNATIVE FOR COST-EFFECTIVENESS ANALYSIS IN HEALTH CARE
|
Gandjour, A
|
|
2009
|
12 |
Supplement 1 |
p. A22-
1 p.
|
artikel
|
| 171 |
PMC46 A REVIEW OF THE EVOLUTION OF HEALTH ECONOMIC MODELS OF SMOKING CESSATION
|
Fisher, MI
|
|
2009
|
12 |
Supplement 1 |
p. A28-
1 p.
|
artikel
|
| 172 |
PMC37 COMPARISON OF RISK ADJUSTMENT MODELS IN OUTCOMES RESEARCH
|
Baser, O
|
|
2009
|
12 |
Supplement 1 |
p. A393-
1 p.
|
artikel
|
| 173 |
PMC54 ESTIMATING SOCIAL PREFERENCES FOR EQ-5D IN TURKEY : A NOVEL METHOD BASED ON A VALUATION EXCHANGE-RATE MECHANISM
|
Chuang, LH
|
|
2009
|
12 |
Supplement 1 |
p. A397-
1 p.
|
artikel
|
| 174 |
PMC40 ESTIMATING THE NET HERD EFFECT INDUCED BY PCV-VACCINES: A HYPOTHESIS GENERATING STUDY
|
Sauboin, C
|
|
2009
|
12 |
Supplement 1 |
p. A394-
1 p.
|
artikel
|
| 175 |
PMC73 EVALUATION OF GLP-1 PRODUCT ATTRIBUTES IN TREATING PEOPLE WITH TYPE-2 DIABETES IN US: COMPARING TIME-TRADEOFF AND WILLINGNESS-TO-PAY METHODOLOGIES
|
Zanutto, E
|
|
2009
|
12 |
Supplement 1 |
p. A33-
1 p.
|
artikel
|
| 176 |
PMC59 PSYCHOMETRIC ASSESSMENT OF AN INSTRUMENT TO MEASURE PATIENT SATISFACTION WITH MEDICATION THERAPY MANAGEMENT SERVICES
|
Bodhani, A
|
|
2009
|
12 |
Supplement 1 |
p. A30-
1 p.
|
artikel
|
| 177 |
PMC74 QUALITY-ADJUSTED LIFE YEARS SAVED BY PREVENTION OF HEAD INJURY THROUGH ENFORCEMENT OF HELMET LAW
|
Lee, HY
|
|
2009
|
12 |
Supplement 1 |
p. A33-
1 p.
|
artikel
|
| 178 |
PMC9 REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY: AN APPLICATION OF PROPENSITY SCORE MATCHING
|
Exuzides, A
|
|
2009
|
12 |
Supplement 1 |
p. A388-
1 p.
|
artikel
|
| 179 |
PMC32 RELEVANCE OF CONFERENCE ABSTRACTS AND HAND-SEARCHING IN SYSTEMATIC REVIEWS
|
Karia, R
|
|
2009
|
12 |
Supplement 1 |
p. A25-
1 p.
|
artikel
|
| 180 |
PMC91 REPORTING QUALITY OF DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS AND ITS ASSOCIATION WITH THE FUNDING AGENCY
|
Singh, N
|
|
2009
|
12 |
Supplement 1 |
p. A36-
1 p.
|
artikel
|
| 181 |
PMC56 THE EFFECT OF RECALL PERIOD ON CANCER PATIENTS' RATINGS OF THE SEVERITY OF MULTIPLE SYMPTOMS
|
Shi, Q
|
|
2009
|
12 |
Supplement 1 |
p. A30-
1 p.
|
artikel
|
| 182 |
PMC71 THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY
|
Schlander, M
|
|
2009
|
12 |
Supplement 1 |
p. A400-
1 p.
|
artikel
|
| 183 |
PMC6 THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS
|
Singh, N
|
|
2009
|
12 |
Supplement 1 |
p. A387-
1 p.
|
artikel
|
| 184 |
PMC23 UNDERESTIMATION OF UNCERTAINTY IN COST-EFFECTIVENESS ACCEPTABILITY CURVES AND EXPECTED VALUE OF INFORMATION ANALYSES
|
Müller, D
|
|
2009
|
12 |
Supplement 1 |
p. A391-
1 p.
|
artikel
|
| 185 |
PMH1 ALPRAZOLAM-RELATED DEATHS IN WEST VIRGINIA
|
Shah, N
|
|
2009
|
12 |
Supplement 1 |
p. A172-
1 p.
|
artikel
|
| 186 |
PMH14 ALZHEIMER'S DISEASE: A PHARMACOEPIDEMIOLOGICAL STUDY
|
Truter, I
|
|
2009
|
12 |
Supplement 1 |
p. A352-A353
nvt p.
|
artikel
|
| 187 |
PMH84 AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID BENEFICIARIES
|
Esposito, D
|
|
2009
|
12 |
Supplement 1 |
p. A188-
1 p.
|
artikel
|
| 188 |
PMH65 ASSOCIATION BETWEEN EARLY ANTIDEPRESSANT RESPONSE AND QUALITY OF LIFE AMONG PATIENT WITH DEPRESSION: RESULTS FROM A 1-YEAR FOLLOW-UP LARGE EPIDEMIOLOGICAL STUDY
|
Roca, M
|
|
2009
|
12 |
Supplement 1 |
p. A363-
1 p.
|
artikel
|
| 189 |
PMH48 BURDEN OF ILLNESS OF DEPRESSION SYMPTOMS AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS
|
Bolge, SC
|
|
2009
|
12 |
Supplement 1 |
p. A181-
1 p.
|
artikel
|
| 190 |
PMH16 COST-BENEFIT ANALYSIS OF FOUR ANTIPSYCHOTIC DRUGS FOR THE TREATMENT OF SCHIZOPHRENIA IN COLOMBIA
|
Rosselli, D
|
|
2009
|
12 |
Supplement 1 |
p. A175-
1 p.
|
artikel
|
| 191 |
PMH4 COSTS AND CONSEQUENCES FOR METABOLIC SYNDROME, DIABETES AND CORONARY HEART DISEASE (CHD) RISK AMONG SCHIZOPHRENIA PATIENTS TREATED WITH ARIPIPRAZOLE VERSUS OLANZAPINE IN BRAZIL
|
Litalien, G
|
|
2009
|
12 |
Supplement 1 |
p. A520-A521
nvt p.
|
artikel
|
| 192 |
PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND—ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA
|
Soini, EJ
|
|
2009
|
12 |
Supplement 1 |
p. A359-
1 p.
|
artikel
|
| 193 |
PMH19 ECONOMIC ASSESSMENT OF SECOND-LINE TREATMENT: SWITCHING FROM A GENERIC SSRI TO ESCITALOPRAM, AN SNRI, OR ANOTHER GENERIC SSRI BY PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
|
Marynchenko, M
|
|
2009
|
12 |
Supplement 1 |
p. A175-A176
nvt p.
|
artikel
|
| 194 |
PMH33 ECONOMIC IMPLICATION OF DOSE ESCALATION IN DEPRESSED PATIENTS TREATED WITH ESCITALOPRAM OR VENLAFAXINE XR
|
Yu, AP
|
|
2009
|
12 |
Supplement 1 |
p. A178-
1 p.
|
artikel
|
| 195 |
PMH65 EFFECT OF HEALTH INSURANCE COVERAGE AND DEPRESSION ON PRESCRIPTION MEDICATION USE IN PATIENTS WITH CHRONIC MEDICAL DISORDERS
|
Sankaranarayanan, J
|
|
2009
|
12 |
Supplement 1 |
p. A185-
1 p.
|
artikel
|
| 196 |
PMH59 FURTHER VALIDITY EVIDENCES OF THE GENERALIZED ANXIETY DISORDER—7 SCALE (GAD-7)
|
Ruiz, MA
|
|
2009
|
12 |
Supplement 1 |
p. A362-
1 p.
|
artikel
|
| 197 |
PMH79 IDENTIFICATION OF TREATMENT RESISTANT DEPRESSION IN CLAIMS DATA: A COMPARISON OF METHODS
|
Gibson, TB
|
|
2009
|
12 |
Supplement 1 |
p. A187-
1 p.
|
artikel
|
| 198 |
PMH28 INITIAL PRESCRIPTION DOSE OF DULOXETINE AND HOSPITALIZATION AND HEALTH CARE COSTS FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER
|
Liu, X
|
|
2009
|
12 |
Supplement 1 |
p. A355-
1 p.
|
artikel
|
| 199 |
PMH31 MEASURING THE ECONOMIC BURDEN OF DEPRESSION USING PATIENT RECORDS
|
Jacobs, P
|
|
2009
|
12 |
Supplement 1 |
p. A356-
1 p.
|
artikel
|
| 200 |
PMH1 META-ANALYSIS OF CLINICAL OUTCOMES FROM GUIDELINE-RECOMMENDED PHARMACOTHERAPIES FOR GENERALIZED ANXIETY DISORDER (GAD)
|
Bereza, BG
|
|
2009
|
12 |
Supplement 1 |
p. A520-
1 p.
|
artikel
|
| 201 |
PMH51 PSYCHOMETRIC PROPERTIES OF THE LIFE PARTICIPATION SCALE FOR ADULTS ASSESSING DEFICITS IN ADAPTIVE FUNCTIONING
|
Saylor, KE
|
|
2009
|
12 |
Supplement 1 |
p. A182-
1 p.
|
artikel
|
| 202 |
PMH62 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER
|
Maurino, J
|
|
2009
|
12 |
Supplement 1 |
p. A362-
1 p.
|
artikel
|
| 203 |
PM1 PERSONALIZED MEDICINE: FACTORS INFLUENCING REIMBURSEMENT
|
Meckley, LM
|
|
2009
|
12 |
Supplement 1 |
p. A3-
1 p.
|
artikel
|
| 204 |
PMS41 AN ASSESSMENT OF SELF REPORTED OUTCOMES IN A NATIONALLY REPRESENTATIVE SAMPLE OF ELDERLY PERSON DIAGNOSED WITH RHEUMATOID ARTHRITIS
|
Rajpura, JR
|
|
2009
|
12 |
Supplement 1 |
p. A71-
1 p.
|
artikel
|
| 205 |
PMS16 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
|
Saggia, MG
|
|
2009
|
12 |
Supplement 1 |
p. A436-
1 p.
|
artikel
|
| 206 |
PMS26 CHARACTERISTICS AND HEALTH CARE UTILIZATION RESULTING FROM INJECTION SITE REACTIONS WITH ANTI-TNF TREATMENTS FOR RHEUMATOID ARTHRITIS: AN ANALYSIS OF CASES AT AN URBAN TEACHING HOSPITAL
|
Pizzi, LT
|
|
2009
|
12 |
Supplement 1 |
p. A68-
1 p.
|
artikel
|
| 207 |
PMS33 COST-BENEFIT ANALYSIS OF MANAGEMENT STRATEGIES TO REDUCE ROAD TRAFFIC INJURIES
|
Srijariya, W
|
|
2009
|
12 |
Supplement 1 |
p. A439-
1 p.
|
artikel
|
| 208 |
PMS52 COST-MINIMIZATION ANALYSIS OF BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PATIENT PERSPECTIVE IN BRAZIL
|
Saggia, MG
|
|
2009
|
12 |
Supplement 1 |
p. A442-A443
nvt p.
|
artikel
|
| 209 |
PMS49 COST-UTILITY ANALYSIS OF LEFLUNOMIDE (ARAVA) IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
|
Plisko, R
|
|
2009
|
12 |
Supplement 1 |
p. A442-
1 p.
|
artikel
|
| 210 |
PMS16 ESTIMATION OF LIFE EXPECTANCIES AND LOSS OF LIFE EXPECTANCIES FOR WORKERS WITH PERMANENT OCCUPATIONAL DISABILITY OF UPPER AND LOWER LIMBS: A FOLLOW-UP STUDY OF 69,964 WORKERS FOR 21 YEARS
|
Lin, SH
|
|
2009
|
12 |
Supplement 1 |
p. A66-
1 p.
|
artikel
|
| 211 |
PMS13 ESTUDIO FARMACOECONÓMICO DE LOS TRATAMIENTOS ACIDO ZOLEDRÓNICO, RISEDRONATO, ALENDRONATO E IBANDRONATO EN EL MANEJO DE LA OSTEOPOROSIS EN MUJERES POSMENOPÁUSICAS EN VENEZUELA.
|
Fernandez, Y
|
|
2009
|
12 |
Supplement 1 |
p. A523-
1 p.
|
artikel
|
| 212 |
PMS90 FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT
|
Le Lay, K
|
|
2009
|
12 |
Supplement 1 |
p. A450-
1 p.
|
artikel
|
| 213 |
PMS58 FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS' DISEASE MANAGEMENT
|
Nasonov, E
|
|
2009
|
12 |
Supplement 1 |
p. A74-
1 p.
|
artikel
|
| 214 |
PMS93 GREEK NHS CAPACITY CONSTRAINTS REGARDING IV TREATMENT FOR RHEUMATOID ARTHRITIS PATIENTS
|
Athanasakis, K
|
|
2009
|
12 |
Supplement 1 |
p. A451-
1 p.
|
artikel
|
| 215 |
PMS62 INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS
|
Maurel, F
|
|
2009
|
12 |
Supplement 1 |
p. A444-A445
nvt p.
|
artikel
|
| 216 |
PMS76 PATIENT REPORTED QUALITY-OF-LIFE ISSUES IN MYOTONIC DYSTROPHY TYPE-1 (DMI): A FIRST STEP IN THE DEVELOPMENT OF A DISEASE-SPECIFIC INSTRUMENT
|
Heatwole, C
|
|
2009
|
12 |
Supplement 1 |
p. A447-
1 p.
|
artikel
|
| 217 |
PMS13 PREVALENCE OF FIBROMYALGIA IN RUSSIA
|
Le Lay, K
|
|
2009
|
12 |
Supplement 1 |
p. A66-
1 p.
|
artikel
|
| 218 |
PMS2 SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE: ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING
|
Golicki, D
|
|
2009
|
12 |
Supplement 1 |
p. A433-
1 p.
|
artikel
|
| 219 |
PND13 A COST-CONSEQUENCES ANALYSIS OF THE IMPACT OF A-RATED ANTI-EPILEPTIC DRUG SWITCHING: THE MANAGED CARE PLAN PERSPECTIVE
|
Hansen, RN
|
|
2009
|
12 |
Supplement 1 |
p. A192-
1 p.
|
artikel
|
| 220 |
PND28 ADHERENCE AS A PREDICTOR OF THE UTILIZATION OF HEALTH CARE RESOURCES IN A MULTIPLE SCLEROSIS POPULATION USING INTERFERONS
|
Faris, R
|
|
2009
|
12 |
Supplement 1 |
p. A370-
1 p.
|
artikel
|
| 221 |
PND6 COMPARISON OF COSTS FOR INTERFERON BETA 1-A AND NATALIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
|
Kozma, C
|
|
2009
|
12 |
Supplement 1 |
p. A190-
1 p.
|
artikel
|
| 222 |
PND25 COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMER'S DISEASE IN NORWAY
|
Toumi, M
|
|
2009
|
12 |
Supplement 1 |
p. A370-
1 p.
|
artikel
|
| 223 |
PND10 COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM
|
Getsios, D
|
|
2009
|
12 |
Supplement 1 |
p. A191-
1 p.
|
artikel
|
| 224 |
PND41 DETECTION OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY REPORTS ASSOCIATED WITH NATALIZUMAB PRE- AND POST-RISK MINIMIZATION ACTION PLAN FROM ADVERSE EVENT REPORTING SYSTEM DATABASE
|
Gandhi, P
|
|
2009
|
12 |
Supplement 1 |
p. A197-
1 p.
|
artikel
|
| 225 |
PND42 INTERPRETING SCORES ON THE MULTIPLE SCLEROSIS-SPECIFIC PRIMUS AND U-FIS OUTCOME MEASURES
|
Twiss, J
|
|
2009
|
12 |
Supplement 1 |
p. A373-
1 p.
|
artikel
|
| 226 |
PND11 NEW ACTIVA PC® FAMILY: COST ANALYSIS OF THE NEW FEATURES FOR DEEP BRAIN STIMULATION THERAPY (DBS)
|
Valldeoriola, F
|
|
2009
|
12 |
Supplement 1 |
p. A367-
1 p.
|
artikel
|
| 227 |
PND1 RELATIONSHIP BETWEEN ADHERENCE TO INTERFERONS TO TREAT MULTIPLE SCLEROSIS AND THE NUMBER AND SEVERITY OF RELAPSES
|
Faris, R
|
|
2009
|
12 |
Supplement 1 |
p. A365-
1 p.
|
artikel
|
| 228 |
PND27 THE IMPACT OF DIFFERENT STAGES OF MULTIPLE SCLEROSIS ON HEALTH UTILITIES: A SYSTEMATIC REVIEW OF THE LITERATURE
|
Naci, H
|
|
2009
|
12 |
Supplement 1 |
p. A194-A195
nvt p.
|
artikel
|
| 229 |
Predicting an SF-6D Preference-Based Score Using MCS and PCS Scores from the SF-12 or SF-36
|
Hanmer, Janel
|
|
2009
|
12 |
Supplement 1 |
p. 958-966
9 p.
|
artikel
|
| 230 |
Preliminary Validation of an Optimally Weighted Patient-Based Utility Index by Application to Randomized Trials in Breast Cancer
|
Grimison, Peter S.
|
|
2009
|
12 |
Supplement 1 |
p. 967-976
10 p.
|
artikel
|
| 231 |
Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences
|
Huybrechts, Krista F.
|
|
2009
|
12 |
Supplement 1 |
p. 16-19
4 p.
|
artikel
|
| 232 |
Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia
|
Karve, Sudeep
|
|
2009
|
12 |
Supplement 1 |
p. 989-995
7 p.
|
artikel
|
| 233 |
PR4 QUALITY OF LIFE IN PATIENTS WITH EPIDERMOLYSIS BULLOSA
|
Tabolli, S
|
|
2009
|
12 |
Supplement 1 |
p. A485-
1 p.
|
artikel
|
| 234 |
PRS27 ASTHMA-RELATED PRODUCTIVITY LOSSES IN ALBERTA, CANADA
|
Thanh, NX
|
|
2009
|
12 |
Supplement 1 |
p. A125-
1 p.
|
artikel
|
| 235 |
PRS48 A SURVEY OF TOBACCO CESSATION INTERVENTIONS IN THE DENTAL SETTING IN JAPAN: NICOTINE REPLACEMENT THERAPY, ATTITUDES TOWARDS TOBACCO CESSATION EDUCATION, AND BARRIERS TO CESSATION COUNSELING
|
Nakao, H
|
|
2009
|
12 |
Supplement 1 |
p. A307-A308
nvt p.
|
artikel
|
| 236 |
PRS45 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 475: A POPULATION-BASED STUDY
|
Bouza, C
|
|
2009
|
12 |
Supplement 1 |
p. A307-
1 p.
|
artikel
|
| 237 |
PRS21 COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE ALLERGIC ASTHMA
|
Lecomte, P
|
|
2009
|
12 |
Supplement 1 |
p. A302-
1 p.
|
artikel
|
| 238 |
PRS24 INCREMENTAL ASTHMA-RELATED EXPENDITURES ASSOCIATED WITH HIGH UTILIZATION OF SHORT ACTING b-AGONISTS AMONG A COMMERCIALLY INSURED ASTHMATIC POPULATION IN THE U.S.
|
Kamble, S
|
|
2009
|
12 |
Supplement 1 |
p. A125-
1 p.
|
artikel
|
| 239 |
PRS4 INDIRECT COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE AND BUDESONIDE IN THE TREATEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
Pankiewicz, O
|
|
2009
|
12 |
Supplement 1 |
p. A299-
1 p.
|
artikel
|
| 240 |
PRS35 OPINION OF ASTHMA PATIENTS TREATED ACCORDING TO GINA 2006 GUIDELINES—THE EPAGGELIA STUDY
|
Zachariadis, M
|
|
2009
|
12 |
Supplement 1 |
p. A305-
1 p.
|
artikel
|
| 241 |
PRS10 RETURN ON INVESTMENT FROM SMOKING CESSATION INSURANCE COVERAGE IN THE WORKPLACE: A CANADIAN EMPLOYER'S PERSPECTIVE
|
Haycox, A
|
|
2009
|
12 |
Supplement 1 |
p. A122-
1 p.
|
artikel
|
| 242 |
PRS37 WHICH SMOKERS GET ADVICE TO QUIT? VARIABLES ASSOCIATED WITH PHYSICIAN ADVICE FOR SMOKING CESSATION
|
Gause, D
|
|
2009
|
12 |
Supplement 1 |
p. A127-
1 p.
|
artikel
|
| 243 |
PSS15 CHANGES IN HEALTH RELATED UTILITY AMONG ADULTS WITH ATOPIC DERMATITIS TREATED WITH TACROLIMUS OINTMENT COMPARED TO A STANDARD CORTICOSTEROID REGIMEN
|
Poole, CD
|
|
2009
|
12 |
Supplement 1 |
p. A77-
1 p.
|
artikel
|
| 244 |
PSS25 COST-EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR MODERATE TO SEVERE PSORIASIS
|
Carretero, G
|
|
2009
|
12 |
Supplement 1 |
p. A457-
1 p.
|
artikel
|
| 245 |
PSS22 COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND SKIN-STRUCTURE INFECTION TREATMENT IN MEXICO
|
Baca-Muro, VI
|
|
2009
|
12 |
Supplement 1 |
p. A456-
1 p.
|
artikel
|
| 246 |
PSS2 COSTO-EFECTIVIDAD DEL USO DE ETANERCEPT VS LOS ANTICUERPOS MONOCLONALES ANTI-TNF EN PACIENTES CON PSORIASIS EN PLACAS EN MÉXICO
|
Aguirre, A
|
|
2009
|
12 |
Supplement 1 |
p. A526-
1 p.
|
artikel
|
| 247 |
PSS8 COSTS-OF-ILLNESS OF ULCUS CRURIS IN GERMANY: RESULTS OF TWO APPROACHES
|
Purwins, S
|
|
2009
|
12 |
Supplement 1 |
p. A453-
1 p.
|
artikel
|
| 248 |
PSS18 LINGUISTIC VALIDATION OF THE ATTENTION AND PERFORMANCE SELF-ASSESSMENT SCALE, APSA, FOR USE IN INTERNATIONAL STUDIES
|
Montigny, C
|
|
2009
|
12 |
Supplement 1 |
p. A78-
1 p.
|
artikel
|
| 249 |
PSS39 PSORIASIS: AN EPIDEMIOLOGIC EVALUATION OF DISEASE BURDEN IN 590 PATIENTS
|
Feneron, D
|
|
2009
|
12 |
Supplement 1 |
p. A459-A460
nvt p.
|
artikel
|
| 250 |
PSY24 A COST CONSEQUENCE EVALUATION OF TWO MODELS OF CARE OF OUTPATIENTS WITH CHRONIC NEUROPATHIC PAIN IN NEUROLOGY SETTINGS IN SPAIN: GENERAL CLINICS VERSUS SPECIALIZED PAIN CLINICS
|
Matías-Guiu, J
|
|
2009
|
12 |
Supplement 1 |
p. A379-
1 p.
|
artikel
|
| 251 |
PSY27 COST-EFFECTIVENESS OF ANTIGUNGAL PROPHYLAXIS WITH POSACONAZOLE VERSUS STANDARD AZOLE THERAPY IN THE PREVENTION OF INVASIVE FUNGAL INFECTIONS AMONG HIGH RISK HAEMATOLOGY PATIENTS IN CZECH REPUBLIC
|
Suchankova, E
|
|
2009
|
12 |
Supplement 1 |
p. A380-
1 p.
|
artikel
|
| 252 |
PSY21 COST-EFFECTIVENESS OF PREGABALIN IN PATIENTS WITH FIBROMYALGIA: A MEXICAN PERSPECTIVE
|
Arreola-Ornelas, H
|
|
2009
|
12 |
Supplement 1 |
p. A133-A134
nvt p.
|
artikel
|
| 253 |
PSY49 DETERMINANTS OF MEDICAL SERVICES UTILIZATION IN CHRONIC NONCANCER PAIN PATIENTS
|
Puenpatom, RA
|
|
2009
|
12 |
Supplement 1 |
p. A139-
1 p.
|
artikel
|
| 254 |
PSY18 ECONOMIC EVALUATION OF AN INTERNET BASED WEIGHT MANAGEMENT PROGRAM
|
Rasu, R
|
|
2009
|
12 |
Supplement 1 |
p. A133-
1 p.
|
artikel
|
| 255 |
PSY52 ESTIMATION OF CLINICAL AND ECONOMIC IMPACT OF CHRONIC PAIN ON THE BENEFICIARIES OF A PRIVATE HEALTH PLAN IN BRAZIL
|
Reis Neto, JP
|
|
2009
|
12 |
Supplement 1 |
p. A140-
1 p.
|
artikel
|
| 256 |
PSY55 IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE: ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES
|
Bernard, M
|
|
2009
|
12 |
Supplement 1 |
p. A385-A386
nvt p.
|
artikel
|
| 257 |
PSY41 MEASUREMENT OF HEALTH UTILITY VALUES IN THE UK FOR HEALTH STATES RELATED TO IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP)
|
Szende, A
|
|
2009
|
12 |
Supplement 1 |
p. A383-
1 p.
|
artikel
|
| 258 |
PSY35 THE RELATIONSHIP BETWEEN QUALITY OF LIFE, DISABILITY AND PAIN IN PATIENTS WITH FAILED BACK SURGERY SYNDROME
|
Manca, A
|
|
2009
|
12 |
Supplement 1 |
p. A136-
1 p.
|
artikel
|
| 259 |
PSY4 THE USE OF THE HEMOPHILIA AND THROMBOSIS RESEARCH SOCIETY (HTRS) REGISTRY DATA TO UNDERSTAND DIFFERENCES IN RECOMBINANT FACTOR VIIA (RFVIIA) DOSING AND CLINICAL OUTCOMES FOR SPECIFIC JOINT HEMORRHAGES IN HEMOPHILIA
|
Valentino, LA
|
|
2009
|
12 |
Supplement 1 |
p. A130-
1 p.
|
artikel
|
| 260 |
PSY10 TREATING FIBROMYALGIA WITH DULOXETINE: WHAT IS THE ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION ADHERENCE, AND HEALTH CARE COSTS?
|
Wu, N
|
|
2009
|
12 |
Supplement 1 |
p. A377-
1 p.
|
artikel
|
| 261 |
PUK14 HOW DO PATIENTS DESCRIBE THEIR SYMPTOMS OF INTERSTITIAL CYSTITIS/PAINFUL BLADDER SYNDROME (IC/PBS)? QUALITATIVE INTERVIEWS WITH PATIENTS TO SUPPORT THE DEVELOPMENT OF A PATIENT-REPORTED SYMPTOM-BASED SCREENER FOR IC/PBS
|
Abraham, L
|
|
2009
|
12 |
Supplement 1 |
p. A310-
1 p.
|
artikel
|
| 262 |
PUK2 RESTRICTED ACCESS TO DRUGS IS ASSOCIATED WITH LESS OPTIMAL MINERAL METABOLISM CONTROL IN HEMODIALYSIS PATIENTS
|
Mendelssohn, D
|
|
2009
|
12 |
Supplement 1 |
p. A198-
1 p.
|
artikel
|
| 263 |
PUK17 THE FDA DRAFT GUIDANCE ON PATIENT-REPORTED OUTCOMES CAN BE USED TO IMPROVE THE ESTIMATION OF UTILITIES. A CASE STUDY IN CHRONIC KIDNEY DISEASE
|
Lloyd, A
|
|
2009
|
12 |
Supplement 1 |
p. A201-
1 p.
|
artikel
|
| 264 |
RA4 METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST GENERATION ADOLESCENTS (12–17) IN THE UNITED STATES
|
Hufstader, MA
|
|
2009
|
12 |
Supplement 1 |
p. A18-
1 p.
|
artikel
|
| 265 |
Recommendations on Evidence Needed to Support Measurement Equivalence between Electronic and Paper-Based Patient-Reported Outcome (PRO) Measures: ISPOR ePRO Good Research Practices Task Force Report
|
Coons, Stephen Joel
|
|
2009
|
12 |
Supplement 1 |
p. 419-429
11 p.
|
artikel
|
| 266 |
Relapse and Long-Acting Injectable Risperidone: A 1-Year Mirror Image Study with a National Claims Database in Taiwan
|
Su, Kuan-Pin
|
|
2009
|
12 |
Supplement 1 |
p. S118-S121
4 p.
|
artikel
|
| 267 |
Reliability of the Discrete Choice Experiment at the Input and Output Level in Patients with Rheumatoid Arthritis
|
Skjoldborg, Ulla Slothuus
|
|
2009
|
12 |
Supplement 1 |
p. 153-158
6 p.
|
artikel
|
| 268 |
Resource Utilization and Costs of Schizophrenia Patients Treated with Olanzapine versus Quetiapine in a Medicaid Population
|
Yu, Andrew P.
|
|
2009
|
12 |
Supplement 1 |
p. 708-715
8 p.
|
artikel
|
| 269 |
RR3 USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER (BUD/FM DPI) VERSUS TIOTROPIUM DPI
|
Blais, L
|
|
2009
|
12 |
Supplement 1 |
p. A19-
1 p.
|
artikel
|
| 270 |
The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III
|
Stevenson, Matt D.
|
|
2009
|
12 |
Supplement 1 |
p. 1100-1105
6 p.
|
artikel
|
| 271 |
The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire
|
Doward, Lynda C.
|
|
2009
|
12 |
Supplement 1 |
p. 139-145
7 p.
|
artikel
|
| 272 |
The Health Value and Cost of Care for Major Depression
|
Watkins, Katherine E.
|
|
2009
|
12 |
Supplement 1 |
p. 65-72
8 p.
|
artikel
|
| 273 |
Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions: An Application to Vasomotor Symptoms
|
Johnson, F. Reed
|
|
2009
|
12 |
Supplement 1 |
p. 146-152
7 p.
|
artikel
|
| 274 |
Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale
|
Luo, Xuemei
|
|
2009
|
12 |
Supplement 1 |
p. 580-586
7 p.
|
artikel
|
| 275 |
Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations
|
Göhler, Alexander
|
|
2009
|
12 |
Supplement 1 |
p. 185-187
3 p.
|
artikel
|
| 276 |
VA2 COST EFFECTIVENESS ANALYSIS OF THE NEW 10-VALENT PNEUMOCOCCAL NON-TYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN-D CONJUGATE VACCINE (PHID-CV) IN CANADA
|
Ismaila, AS
|
|
2009
|
12 |
Supplement 1 |
p. A9-
1 p.
|
artikel
|
| 277 |
What Is the Best Strategy for Diagnosis and Treatment of Helicobacter pylori in the Prevention of Recurrent Peptic Ulcer Bleeding? A Cost-Effectiveness Analysis
|
Gené, Emili
|
|
2009
|
12 |
Supplement 1 |
p. 759-762
4 p.
|
artikel
|
| 278 |
WP3 ASSESSING THE WILLINGNESS-TO-PAY (WTP) FOR INTRADERMAL INFLUENZA VACCINATION IN AUSTRALIA USING DISCRETE CHOICE METHODOLOGY
|
Adams, J
|
|
2009
|
12 |
Supplement 1 |
p. A237-
1 p.
|
artikel
|
Tijdschrift beschrijving